skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.05e (Release date: 2017-05-30)
SearchBox Top
SearchBox Bottom
ALK Inhibitor ASP3026 (Code C116727)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: ALK Inhibitor ASP3026

Definition: An orally available, small molecule inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon oral administration, ASP3026 binds to and inhibits ALK tyrosine kinase, ALK fusion proteins and ALK point mutation variants. Inhibition of ALK leads to the disruption of ALK-mediated signaling and the inhibition of cell growth in ALK-expressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK is not expressed in healthy adult human tissue but ALK dysregulation and gene rearrangements are associated with a series of tumors. Additionally, ALK mutations are associated with acquired resistance to small molecule tyrosine kinase inhibitors.

Display Name: ALK Inhibitor ASP3026

Label: ALK Inhibitor ASP3026

NCI Thesaurus Code: C116727 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3896911  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
ALK Inhibitor ASP3026

External Source Codes: 
CAS Registry Number 1097917-15-1 (see NLM ChemIDplus info)
PDQ Closed Trial Search ID 694592
PDQ Open Trial Search ID 694592 (check for NCI PDQ open clinical trial info)
UMLS CUI C3896911

Other Properties:
     Name Value (qualifiers indented underneath)
code C116727
Contributing_Source CTRP
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom